Chimeric antigen receptor T cell immunotherapy for prostate cancer has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy; furthermore, new developments could improve the efficacy of chimeric antigen receptor T cell therapy and this treatment could also be applied as focal therapy for this disease.
In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and…
In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and…
Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum-refractory urothelial carcinoma (UC).To eva…
This genetic association study examines the association between variants of established prostate cancer risk genes and the risk of aggressive prostate cancer.
Background Treatment decisions for localized prostate cancer must balance patient preferences, oncologic risk, and preservation of sexual, urinary and bowel function. While Active Surveillance (AS)…
A global team of experts including from the University of Melbourne has made ten recommendations to urgently tackle the worldwide decline in male fertility.
Field cancerization is characterized by areas of normal tissue affected by mutated clones. Bladder field cancerization may explain the development and…
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to…
Approximately two-thirds of small, indeterminate lesions of the testes might be benign and not require radical orchidectomy. Management strategies are evolving to include vigilant active…
This prognostic study assesses the prognostic and predictive value of the modified Glasgow prognostic score during treatment in patients with metastatic renal cell carcinoma.
